The Lille model:: A new tool for therapeutic strategy in patients with severe alcoholic hepatitis treated with steroids

被引:538
作者
Louvet, Alexandre
Naveau, Sylvie
Abdelnour, Marcelle
Ramond, Marie-Jose
Diaz, Emmanuel
Fartoux, Laetitia
Dharancy, Sebastien
Texier, Frederic
Hollebecque, Antoine
Serfaty, Lawrence
Boleslawski, Emmanuel
Deltenre, Pierre
Canva, Valerie
Pruvot, Francois-Rene
Mathurin, Philippe
机构
[1] CHRU Lille, Hop Claude Huriez, Serv Hepatogastroenterol, F-59037 Lille, France
[2] Hop Antoine Beclere, Clamart, France
[3] Hop Beaujon, Clichy, France
[4] Hop Germon & Gauthier Bethune, Paris, France
[5] Hop St Antoine, F-75571 Paris, France
[6] Serv Chirurg Digest & Transplantat, Lille, France
[7] Univ Lille 2, Unite Inserm 795, Lille, France
[8] Univ Paris 11, Orsay, France
关键词
D O I
10.1002/hep.21607
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Early identification of patients with severe (discriminant function >= 32) alcoholic hepatitis (AH) not responding to corticosteroids is crucial. We generated a specific prognostic model (Lille model) to identify candidates early on for alternative therapies. Three hundred twenty patients with AH prospectively treated by corticosteroids were included in the development cohort and 118 in its validation. Baseline data and a change in bilirubin at day 7 were tested. The model was generated by logistic regression. The model combining six reproducible variables (age, renal insufficiency, albumin, prothrombin time, bilirubin, and evolution of bilirubin at day 7) was highly predictive of death at 6 months (P < 0.000001). The area under the receiver operating characteristic (AUROC) curve of the Lille model was 0.89 +/- 0.02, higher than the Child-Pugh (0.62 +/- 0.04, P < 0.00001) or Maddrey scores (0.66 +/- 0.04, P < 0.00001). In the validation cohort, its AUROC was 0.85 +/- 0.04, still higher than the other models, including MELD (0.72 +/- 0.05, P = 0.01) and Glasgow scores (0.67 +/- 0.05, P = 0.0008). Patients above the ideal cutoff of 0.45 showed a marked decrease in 6-month survival as compared with others: 25% +/- 3.8% versus 85% +/- 2.5%, P < 0.0001. This cutoff was able to identify approximately 75% of the observed deaths. Conclusion: In the largest cohort to date of patients with severe AH, we demonstrate that the term "nonresponder" can now be extended to patients with a Lille score above 0.45, which corresponds to 40% of cases. Early identification of subjects with substantial risk of death according to the Lille model will improve management of patients suffering from severe AH and will aid in the design of future studies for alternative therapies.
引用
收藏
页码:1348 / 1354
页数:7
相关论文
共 23 条
[1]
Pentoxifylline improves short-term survival in severe acute alcoholic hepatitis: A double-blind, placebo-controlled trial [J].
Akriviadis, E ;
Botla, R ;
Briggs, W ;
Han, S ;
Reynolds, T ;
Shakil, O .
GASTROENTEROLOGY, 2000, 119 (06) :1637-1648
[2]
OBSERVER VARIATION IN ASSESSMENT OF LIVER BIOPSIES OF ALCOHOLIC PATIENTS [J].
BEDOSSA, P ;
POYNARD, T ;
NAVEAU, S ;
MARTIN, ED ;
AGOSTINI, H ;
CHAPUT, JC .
ALCOHOLISM-CLINICAL AND EXPERIMENTAL RESEARCH, 1988, 12 (01) :173-178
[3]
METHYLPREDNISOLONE THERAPY IN PATIENTS WITH SEVERE ALCOHOLIC HEPATITIS - A RANDOMIZED MULTICENTER TRIAL [J].
CARITHERS, RL ;
HERLONG, F ;
DIEHL, AM ;
SHAW, EW ;
COMBES, B ;
FALLON, HJ ;
MADDREY, WC .
ANNALS OF INTERNAL MEDICINE, 1989, 110 (09) :685-690
[4]
MELD accurately predicts mortality in patients with alcoholic hepatitis [J].
Dunn, W ;
Jamil, LH ;
Brown, LS ;
Wiesner, RH ;
Kim, WR ;
Menon, KVN ;
Malinchoc, M ;
Kamath, PS ;
Shah, V .
HEPATOLOGY, 2005, 41 (02) :353-358
[5]
Low-grade steatosis and major changes in portal flow as new prognostic factors in steroid-treated alcoholic hepatitis [J].
Duvoux, C ;
Radier, C ;
Roudot-Thoraval, F ;
Maille, FO ;
Anglade, MC ;
Van Nhieu, JT ;
Rosa, I ;
Hospitel, S ;
Abd-Alsamad, I ;
Sitruk, W ;
Seror, O ;
Ziol, M ;
Blondon, H ;
Dhumeaux, D ;
Richardet, JP .
HEPATOLOGY, 2004, 40 (06) :1370-1378
[6]
Analysis of factors predictive of mortality in alcoholic hepatitis and derivation and validation of the Glasgow alcoholic hepatitis score [J].
Forrest, EH ;
Evans, CDJ ;
Stewart, S ;
Phillips, M ;
Oo, YH ;
McAvoy, NC ;
Fisher, NC ;
Singhal, S ;
Brind, A ;
Haydon, G ;
O'Grady, J ;
Day, CP ;
Hayes, PC ;
Murray, LS ;
Morris, AJ .
GUT, 2005, 54 (08) :1174-1179
[7]
DO CORTICOSTEROIDS REDUCE MORTALITY FROM ALCOHOLIC HEPATITIS - A METAANALYSIS OF THE RANDOMIZED TRIALS [J].
IMPERIALE, TF ;
MCCULLOUGH, AJ .
ANNALS OF INTERNAL MEDICINE, 1990, 113 (04) :299-307
[8]
A model to predict survival in patients with end-stage liver disease [J].
Kamath, PS ;
Wiesner, RH ;
Malinchoc, M ;
Kremers, W ;
Therneau, TM ;
Kosberg, CL ;
D'Amico, G ;
Dickson, ER ;
Kim, WR .
HEPATOLOGY, 2001, 33 (02) :464-470
[9]
Is liver transplantation an appropriate treatment for acute alcoholic hepatitis? [J].
Lucey, MR .
JOURNAL OF HEPATOLOGY, 2002, 36 (06) :829-831
[10]
MADDREY WC, 1978, GASTROENTEROLOGY, V75, P193